SML3666
AMP-Deoxynojirimycin
≥97% (HPLC)
别名:
AMP-dNJ, AMP-dNM, (2R,3R,4R,5S)-2-(Hydroxymethyl)-1-[5-(tricyclo[3.3.1.13,7]dec-1-ylmethoxy)pentyl]-3,4,5-piperidinetriol, AMP-DNJ, AMP-DNM, Adamantane-pentyl-DNM, Adamantane-pentyl-dNM, MZ-21, N-(5′-Adamantane-1′-yl-methoxy)pentyl-1-deoxynojirimycin; (2R,3R,4R,5S)-1-[5-(1-Adamantylmethoxy)pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol, N-(5-Adamantane-1-yl-methoxy)pentyl-1-deoxynojirimycin; N-(5-Adamantane-1-yl-methoxy)pentyl)-DNM
登录查看公司和协议定价
所有图片(2)
About This Item
推荐产品
品質等級
化驗
≥97% (HPLC)
形狀
powder
儲存條件
desiccated
顏色
white to beige
溶解度
DMSO: 2 mg/mL, clear
儲存溫度
-10 to -25°C
SMILES 字串
O[C@@H]1[C@H](N(C[C@@H]([C@H]1O)O)CCCCCOCC2(C3)C[C@@H](C4)C[C@H]3C[C@@H]4C2)CO
生化／生理作用
AMP-deoxynojirimycin (AMP-DNM) is an orally available iminosugar that acts as a reversible, potent and selective inhibitor against the non-lysosomal glucosylceramidase GBA2 (IC50 = 1.7 nM) over the glucosylceramide synthase (GCS, UGCG), ER alpha-glucosidases, the lysosomal glucocerebrosidase GBA (IC50 = 0.16 μM) and alpha-glucosidase GAA (IC50 = 0.87 μM). AMP-DNM selectively inhibits cellular GBA2 in cultures (GBA2/GBA IC50 = 0.3 nM/100 nM; human melanoma cells) and exhibits in vivo therapeutic efficacy in murine models of obesity (100 mg/kg/day p.o.) and colitis (10-50 mg/kg/day via i.p. or 1.25-6.25g/kg chow).
注意
Hygroscopic
儲存類別代碼
11 - Combustible Solids
水污染物質分類（WGK）
WGK 3
閃點（°F）
Not applicable
閃點（°C）
Not applicable
Inhibition of glycolipid biosynthesis by N-(5-adamantane-1-yl-methoxy-pentyl)-deoxynojirimycin protects against the inflammatory response in hapten-induced colitis
International Immunopharmacology, 4(7), 939-951 (2004)
Reduction of glycosphingolipid biosynthesis stimulates biliary lipid secretion in mice
Hepatology, 49(2), 637-645 (2009)
Cytosolic glucosylceramide regulates endolysosomal function in Niemann-Pick type C disease
Neurobiology of Disease, 127, 242-252 (2019)
Species-specific differences in nonlysosomal glucosylceramidase GBA2 function underlie locomotor dysfunction arising from loss-of-function mutations
The Journal of Biological Chemistry, 294(11), 3853-3871 (2019)
Treatment of genetically obese mice with the iminosugar N-(5-adamantane-1-yl-methoxy-pentyl)-deoxynojirimycin reduces body weight by decreasing food intake and increasing fat oxidation
Metabolism, Clinical and Experimental, 61(1), 99-107 (2012)
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门